Hydrogen Therapy Boosts Immune Recovery After Brain Surgery
- Authors
- Hui-Fu Hsu, Ruei-Yang Hu, Jeng-Wei Lu, Dueng-Yuan Hueng, Yi-Jing Ho, Shan-Wen Lui, Ting-Yu Hsieh, Kuang-Yih Wang, Hsiao-Chen Liu, Feng-Cheng Liu
- Journal
- In Vivo
- Year
- 2025
- DOI
- 10.21873/invivo.13923
- Study Type
- Human
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- Taiwan
- Health Condition
- Subdural Hematoma
- Body System
- Nervous System
TL;DR
A young man with a serious brain injury showed potential benefits from a new treatment using hydrogen capsules, which seemed to help his immune system without causing harm.
Key Finding
In this single patient case, hydrogen therapy appeared to enhance certain immune markers without causing adverse effects, though standard emergency treatments were the primary drivers of recovery.
Summary
This case report describes a 24-year-old man who survived a severe brain bleed (subdural hematoma) with life-threatening complications after receiving standard emergency treatments plus hydrogen capsules. Researchers measured immune system markers in his blood and found that certain immune cells (regulatory T cells and plasma cells) showed changes that might suggest hydrogen therapy enhanced immune function, though the patient's recovery was primarily due to conventional treatments like surgery and oxygen therapy.
Practical Takeaway
This is a single case report of one patient receiving hydrogen alongside multiple intensive medical interventions for a life-threatening condition—it cannot establish whether hydrogen itself provided benefit. While the immune marker changes are interesting, much larger controlled studies are needed before any conclusions can be drawn about hydrogen's role in treating brain bleeds. This case is too limited to inform personal health decisions.
Abstract
Background/aim: Subdural hematomas (SDH), often caused by head trauma, are serious with high mortality and long-term complications. Studies show that molecular hydrogen has neuroprotective effects, such as reducing oxidative stress, inflammation, and cell death. It may also protect mitochondria, support cell function, and regulate immune responses, making it a promising new treatment option for SDH. However, more research is needed to confirm its effectiveness and create treatment guidelines. Case report: We present a 24-year-old man with SDH, along with a right-sided midline shift, uncal herniation, and dilated left pupil. Conventional treatments-craniectomy, hyperbaric oxygen, therapeutic hypothermia, and stem cell therapy-were essential for stabilizing his condition. In addition, we administered hydrogen capsules as a novel adjunct therapy, beginning daily treatment immediately upon admission. While recovery was primarily due to standard interventions, hydrogen therapy appeared to enhance immune markers, particularly Treg and plasma cells, with no adverse effects. This case indicates that hydrogen therapy may serve as a beneficial addition to established SDH management methods. Conclusion: This case suggests that molecular hydrogen therapy may be a helpful adjunct treatment for SDH with midline shift. Conventional therapies, including craniectomy, hyperbaric oxygen, therapeutic hypothermia, and stem cell therapy, were vital to the patient's recovery, but hydrogen therapy may have contributed by modulating immune responses, particularly Treg and plasma cell activity. While these findings are encouraging, further research is necessary to confirm hydrogen therapy's benefits and its role alongside traditional neurocritical care treatments.